Recognizing the critical need for exceptional preclinical CRO services, I embarked on a journey to establish MediNect Ophtho. Our unique name represents our commitment to connecting medical research experts with Biotech/Biopharma companies.

​

Integrating world-class expertise in specialized areas, such as retinal disease, is essential for small, medium, and large pharma companies. The right knowledge and experience in preclinical study design are key to delivering results that answer the right questions and increase the chances of success in your exit strategy.

​

With my extensive experience working for a young preclinical CRO and a Biotech seeking investment, I have acquired the necessary tools to establish a preclinical CRO that engages and collaborates with Biotech companies to optimize their preclinical portfolio. Our team of Key Opinion Leaders (KOLs), post-doctoral scientists, statisticians, clinicians, animal care staff, and study directors work tirelessly to meet the unique needs of each of our clients.

​

At MediNect, our foundation is built on trust, reliability, and quality. While challenging conversations may arise, we recognize the necessity to form the best relationship to foster product growth and development. Our approach sets us apart from our competitors and enables us to establish lasting partnerships with our clients.

​

I am excited to connect with you to learn more about how we can support your therapeutic development.

 

Best wishes,

​

Dr. James Bojdo